Gastric cancer
Conditions
Interventions
To find out the safety and efficacy of the anti-cancer drug for elderly patients with gastric cancer
Sponsors
Tottori University, Divsion of Surgical Oncology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histopathologically confirmed gastric cancer. 2)Curability A (R0). 3)Stage II (excluded T3N0) / III (Japanese classification). 4)No hepatic, peritoneal, or distant metastasis; no tumor cells in peritoneal fluid on cytologic analysis. 5)age:75. 6)No previous treatment(radiation therapy, chemotherapy, hormone therapy) for cancer except for the initial gastric resection for the primary lesion. 7)Oral administration is possible within 12 weeks after gastric resection. 8)Without any other severe diseases and adequate organ functions. Leu: >=4,000 /mm3, <=ULN Plt: >= 100,000 /mm3 T-bil: <= 1.5 g/dL ALT<=ULNx2.5 AST<=ULNx2.5 Ccr: >= 30 mg/min 9)With written informed consent.
Exclusion criteria
Exclusion criteria: 1)Active double cancer and/or past history of other cancer. 2)Flucytosin, phenytoin, or warfarin potassium administration. 3)Allergic more than and equal to grade3. 4)Patients with significant complications. 5)History of serious allergic reaction with S-1. 6)Men who have willing to become partner's pregnant. 7)Patients with HIV,HBV. 8)Not appropriate for the study at the physician's assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility (Treatment completion rate) | — |
Secondary
| Measure | Time frame |
|---|---|
| OS, RFS, Safety | — |
Countries
Japan
Contacts
Public ContactHiroaki Saito
Tottori University Divsion of Surgical Oncology
Outcome results
None listed